Abstract 2049: Clinically and biologically distinct molecular subtypes of lung squamous cell carcinoma (LUSC)
Authors: Siddiqui Ashar , Stretch Cynthia , Farshidfar Farshad , Bathe Oliver F. 
Published: April 2023

Background: Lung cancer is the leading cause of cancer death worldwide, with LUSC accounting for a third of cases. Stage I and II LUSC is typically treated with resection, and decisions related to adjuvant chemotherapy are related to recurrence risk, which is a function of stage. However, disease stage does not fully capture tumor biology, which may be a more important determinant of recurrence risk. Our objective was to identify biologically significant molecular subgroups of LUSC that more accurately reflect recurrence risk. Methods: Transcriptomic data for resected stage I/II LUSC were obtained from The Cancer Genome Atlas (TCGA). A training set consisting of patients who underwent resection without adjuvant chemotherapy or radiotherapy was used for discovery (N=161). A proprietary machine learning algorithm (HighLifeR™) was used to identify the genes most associated with disease-free survival (DFS). Molecular subgroups were identified by unsupervised clustering of prognostic genes. Functional differences between molecular subgroups were identified by gene set enrichment analysis (GSEA) and Ingenuity Pathway Analysis (IPA). Results: HighLifeR™ identified 60 highly prognostic genes. Two molecular subgroups were identified with significantly different median DFS: a high-risk group with 59.300 months and hazard ratio of 11.551, and a low-risk group that did not reach 50% DFS (log-rank p = 1.96 x 10-5). These subgroups did not differ in age, sex, race, smoking status, or overall stage (p &gt; 0.05). Importantly, univariate and multivariate Cox regression analysis showed that the molecular subgroups outperformed clinical stage in predicting DFS. The molecular subgroups were biologically distinct. On GSEA, the high-risk group was significantly enriched in genes involved in mitotic spindle assembly (NES=1.94, p&lt;0.001); TGFα signaling and PI3K/AKT/mTOR signaling were modestly enriched. IPA pathway analysis demonstrated significant enrichment of numerous pathways linked to neuronal growth and signaling (eg: CREB signaling, S100 signaling, pathways in myelination and synaptogenesis), as well as TGFα signaling and AMPK signaling (all p&lt;0.001). Conclusions: Our prognostic transcriptomic signature identified two biologically distinct molecular subgroups of LUSC. Molecular subgroup classification was more predictive of DFS in stage I and II LUSC than any other clinical or pathological variable. If further validation confirms this, then this biomarker may form the basis of a diagnostic test that helps inform which patients could be considered for adjuvant chemotherapy.

Citation Format: Ashar Siddiqui, Cynthia Stretch, Farshad Farshidfar, Oliver F. Bathe. Clinically and biologically distinct molecular subtypes of lung squamous cell carcinoma (LUSC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2049.